BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 21617232)

  • 1. Impact of common medications on serum total prostate-specific antigen levels and risk group assignment in patients with prostate cancer.
    Nieder C; Norum J; Geinitz H
    Anticancer Res; 2011 May; 31(5):1735-9. PubMed ID: 21617232
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prostate-specific antigen levels in relation to consumption of nonsteroidal anti-inflammatory drugs and acetaminophen: results from the 2001-2002 National Health and Nutrition Examination Survey.
    Singer EA; Palapattu GS; van Wijngaarden E
    Cancer; 2008 Oct; 113(8):2053-7. PubMed ID: 18780337
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum insulin level, disease stage, prostate specific antigen (PSA) and Gleason score in prostate cancer.
    Lehrer S; Diamond EJ; Stagger S; Stone NN; Stock RG
    Br J Cancer; 2002 Sep; 87(7):726-8. PubMed ID: 12232754
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nonsteroidal anti-inflammatory drugs and risk of prostate cancer in the Baltimore Longitudinal Study of Aging.
    Platz EA; Rohrmann S; Pearson JD; Corrada MM; Watson DJ; De Marzo AM; Landis PK; Metter EJ; Carter HB
    Cancer Epidemiol Biomarkers Prev; 2005 Feb; 14(2):390-6. PubMed ID: 15734963
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The influence of statin medications on prostate-specific antigen levels.
    Hamilton RJ; Goldberg KC; Platz EA; Freedland SJ
    J Natl Cancer Inst; 2008 Nov; 100(21):1511-8. PubMed ID: 18957682
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association of percent positive prostate biopsies and perineural invasion with biochemical outcome after external beam radiotherapy for localized prostate cancer.
    Wong WW; Schild SE; Vora SA; Halyard MY
    Int J Radiat Oncol Biol Phys; 2004 Sep; 60(1):24-9. PubMed ID: 15337536
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The impact of hypertriglyceridemia on prostate cancer development in patients aged ≥60 years.
    Hayashi N; Matsushima M; Yamamoto T; Sasaki H; Takahashi H; Egawa S
    BJU Int; 2012 Feb; 109(4):515-9. PubMed ID: 21812901
    [TBL] [Abstract][Full Text] [Related]  

  • 8. No effect of statins on biochemical outcomes after radiotherapy for localized prostate cancer.
    Soto DE; Daignault S; Sandler HM; Ray ME
    Urology; 2009 Jan; 73(1):158-62. PubMed ID: 18722651
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prostate-specific antigen doubling time predicts clinical outcome and survival in prostate cancer patients treated with combined radiation and hormone therapy.
    Lee AK; Levy LB; Cheung R; Kuban D
    Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):456-62. PubMed ID: 15927415
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prostate-cancer-specific survival and clinical progression-free survival in men with prostate cancer treated intermittently with testosterone-inactivating pharmaceuticals.
    Scholz M; Lam R; Strum S; Jennrich R; Johnson H; Trilling T
    Urology; 2007 Sep; 70(3):506-10. PubMed ID: 17905106
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neoadjuvant hormone therapy and external-beam radiation for localized high-risk prostate cancer: the importance of PSA nadir before radiation.
    Ludgate CM; Bishop DC; Pai H; Eldridge B; Lim J; Berthelet E; Blood P; Piercy GB; Steinhoff G
    Int J Radiat Oncol Biol Phys; 2005 Aug; 62(5):1309-15. PubMed ID: 16029786
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biochemical outcome after radical prostatectomy or external beam radiation therapy for patients with clinically localized prostate carcinoma in the prostate specific antigen era.
    D'Amico AV; Whittington R; Malkowicz SB; Cote K; Loffredo M; Schultz D; Chen MH; Tomaszewski JE; Renshaw AA; Wein A; Richie JP
    Cancer; 2002 Jul; 95(2):281-6. PubMed ID: 12124827
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of statins and anticoagulants on prostate cancer aggressiveness.
    Alizadeh M; Sylvestre MP; Zilli T; Van Nguyen T; Guay JP; Bahary JP; Taussky D
    Int J Radiat Oncol Biol Phys; 2012 Jul; 83(4):1149-53. PubMed ID: 22270166
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Free-to-total prostate-specific antigen ratio as a predictor of non-organ-confined prostate cancer (stage pT3).
    Aus G; Becker C; Lilja H; Khatami A; Pihl CG; Hugosson J
    Scand J Urol Nephrol; 2003; 37(6):466-70. PubMed ID: 14675918
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predictors of mortality after androgen-deprivation therapy in patients with rapidly rising prostate-specific antigen levels after local therapy for prostate cancer.
    Rodrigues NA; Chen MH; Catalona WJ; Roehl KA; Richie JP; D'Amico AV
    Cancer; 2006 Aug; 107(3):514-20. PubMed ID: 16795068
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reduction of prostate-specific antigen after tamsulosin treatment in patients with elevated prostate-specific antigen and lower urinary tract symptoms associated with low incidence of prostate cancer at biopsy.
    Tubaro A; De Nunzio C; Mariani S; Trucchi A; Miano R; Vicentini C; Miano L
    Urology; 2010 Aug; 76(2):436-41. PubMed ID: 20538320
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effect of statins on serum prostate specific antigen levels in a cohort of airline pilots: a preliminary report.
    Cyrus-David MS; Weinberg A; Thompson T; Kadmon D
    J Urol; 2005 Jun; 173(6):1923-5. PubMed ID: 15879782
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Initial decline in hemoglobin during neoadjuvant hormonal therapy predicts for early prostate specific antigen failure following radiation and hormonal therapy for patients with intermediate and high-risk prostate cancer.
    D'Amico AV; Saegaert T; Chen MH; Renshaw AA; George D; Oh W; Kantoff PW
    Cancer; 2002 Jul; 95(2):275-80. PubMed ID: 12124826
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of common medications on serum total prostate-specific antigen levels: analysis of the National Health and Nutrition Examination Survey.
    Chang SL; Harshman LC; Presti JC
    J Clin Oncol; 2010 Sep; 28(25):3951-7. PubMed ID: 20679596
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Statins, especially atorvastatin, may favorably influence clinical presentation and biochemical progression-free survival after brachytherapy for clinically localized prostate cancer.
    Moyad MA; Merrick GS; Butler WM; Wallner KE; Galbreath RW; Kurko B; Adamovich E
    Urology; 2005 Dec; 66(6):1150-4. PubMed ID: 16360430
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.